BioSpace News Archive

Policy

Biopharma Update on the Novel Coronavirus: August 26

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.

August 25, 2020
·
4 min read
·
BioSpace Editorial Staff
Business

ATAI Life Sciences Launches EmpathBio with Focus on PTSD Treatment

ATAI Life Sciences announced on Monday that it has launched EmpathBio, a wholly-owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder.

August 25, 2020
·
3 min read
·
Krystle Vermes
Business

FDA’s Hahn Apologizes for Overstating Benefit of COVID-19 Plasma Treatment

“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma,” Hahn tweeted. “The criticism is entirely justified. What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.”

August 25, 2020
·
4 min read
·
Mark Terry
Drug Development

The Supercomputer Breaking Online Gaming Records and Modeling COVID-19

The Hadean Platform, a distributed computing platform, streamlines running applications via cloud by removing excessive middleware and helping scale the process – a journey that has taken them from the world of gaming to the modeling a pandemic.

August 25, 2020
·
6 min read
·
David Kirk
Policy

FDA Issues CRL for Tricida’s Metabolic Acidosis in CKD Treatment Veverimer

Tricida plans to request a Type A meeting with the FDA, which is expected to take place in the fourth quarter of this year. This meeting will decide the future of veverimer.

August 25, 2020
·
2 min read
·
Alex Keown
Drug Development

Case Report: 33-Year-Old Man Caught COVID-19 Twice

The genetic sequences of the two samples were markedly different, which strengthened the theory that the patient had been infected a second time.

August 25, 2020
·
3 min read
·
Mark Terry
Drug Development

Bristol Myers Squibb’s Idhifa Flunks Acute Myeloid Leukemia Trial

BMS announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care (BSC) compared to conventional care, did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia (r/r AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.

August 25, 2020
·
2 min read
·
Mark Terry
Biotech Beach

Mouse Study Shows Promise in the Potential Regrowth of Joint Cartilage

According to a study published in Nature Medicine on August 17, researchers from the Stanford University School of Medicine have discovered a way to regenerate the cushion of cartilage found in joints.

August 25, 2020
·
3 min read
·
Krystle Vermes
Business

AbbVie Expands Fibrotic Disease Partnership With Morphic Therapeutics

Under terms of the licensing deal, Morphic will receive an infusion of $20 million for the license fee along with potential future development milestone payments and royalties from the sales of any commercialized candidates.

August 25, 2020
·
2 min read
·
Alex Keown
Business

AbbVie Taps Harvard University for Viral Infection Research Partnership

AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.

August 25, 2020
·
2 min read
·
Alex Keown